ANZCTR search results

This study will assess the anti-cancer activity of RXC004 given alone in participants with advanced pancreatic cancer whose cancer has worsened following therapy with current standard of care. You may be eligible for this study if you are participating in the Cancer Molecular Screening and Therapeutics (MoST) Program (ACTRN12616000908437) and have RNF43-positive pancreatic ductal adenocarcinoma that has progressed following therapy with current standard of care. All participants will be treated with RXC004. RXC004 capsule strengths are 0.5 mg and 1.0 mg capsules to be taken at a dose of 2mg daily, taken orally and fasted. Participants will be regularly assessed throughout the study in order to monitor safety and tumour response. It is hoped that this study will help increase treatment options for patients with advanced pancreatic cancer.

This Study aims to understand the best way to offer Australian Aboriginal and Torres Strait Islander Peoples lung cancer screening. Who is it for? You may be eligible to join this study if you are an Aboriginal or Terres Strait Islander person aged between 50 to 80 years old, and at high risk for developing lung cancer. Study details. All participants who complete an eligibility questionnaire and are found to be at high risk of developing lung cancer will be offered a low dose CT chest scan. Participants will be invited to complete a Lung Health Questionnaire, a Quality-of-Life questionnaire on enrolment then an annual health assessment questionnaire for up 10 years. Participants who do not meet the eligibility criteria for a low dose CT chest scan will be invited to participate in the Annual Health Assessment by agreeing to complete a questionnaire every year for up to 10 years. It is hoped that this research project will contribute to lung cancer screening research to detect lung cancer so it can be treated early.

This is a study that will be used to evaluate how effective Telehealth is for patients who are already being followed up in a urological oncology clinic. You may be eligible for this study if you are already a patient who is regularly followed up at the Crown Princess Mary Cancer Centre in Westmead Hospital for a urological cancer condition. Unfortunately, if you are not yet known to the clinic or are awaiting to see a urologist for your first visit, you will not be eligible to participate. Study Details Patients who are eligible for the study will be contacted and informed about the trials aims and methods and informed consent will need to be provided should they wish to participate. Following this, participants will be randomised prior to their next follow up appointment to either a Telehealth group or the standard face-to-face appointment type. They will be notified of their allocation 24 hours prior to their appointment. At the end of the follow up appointment, participants will be asked to completed a validated questionnaire that will help quantify their responses with regards to effectiveness, services provided, efficiency and timing of the appointment, and overall satisfaction. These scores will be de-identified and anonymous. By participating in this trial, we will be able to compare how effective patients find Telehealth vs face-to-face consultations for those suffering from common urological malignancies. We also will assess to see if there are any barriers to the widespread adoption of Telehealth for these common health conditions and if any adverse effects are encountered. This knowledge can help potentiate Telehealth's adaptation to other fields of surgical and medical disciplines as well as providing timely and more efficient care to a greater number of patients within the local health district.

This project aims to evaluate the effectiveness of 'My Toddler and Me', a group-based parenting intervention adapted from Parent-Child Interaction Therapy for Toddlers, in improving outcomes for caregivers and their toddlers (12-24 months old). Additionally, it seeks to assess implementation outcomes to inform future scaling. Furthermore, the study will investigate the role of biological factors, specifically OXTR polymorphisms, in predicting social-emotional and behavioural issues in toddlers and their response to the 'My Toddler and Me' program. The study will recruit 120 parent-child dyads, randomly allocating them to either the 'My Toddler and Me' program or a waitlist control condition. Parents will complete a series of parent-report questionnaires at baseline, post-treatment/waitlist, and a 3-month follow-up.

Clonal haematopoiesis of indeterminant potential (CHIP) is the technical term to describe the expansion of blood cells that results from changes to the genetic code that occur during normal ageing. We are only now beginning to understand what the implications of CHIP are for human health. CHIP has been linked to increased risk of cardiovascular disease. The aim of this study is to examine the blood vessels in the heart and factors in the blood to see if people who have CHIP have faster progression of atherosclerotic cardiovascular disease and other cardiovascular risk factors.

This is a study to assess the efficacy and safety of cyclical testosterone and darolutamide in non-metastatic castration-resistant prostate cancer. Who is it for? You may be eligible for this study if you are an adult male with castrate resistant prostate cancer, with no evidence of metastatic disease (M0) on conventional imaging [Whole Body Bone Scan (WBBS) and Computed Tomography (CT) scan at screening] and prostate specific antigen (PSA) only progression on darolutamide. Study details Study participants will receive cyclical treatment with intramuscular (IM) testosterone, darolutamide and ongoing medical/surgical castration. This will be delivered in 56-day cycles until evidence of metastatic disease on conventional imaging unless treated beyond progression. Participants will be asked to provide blood samples, complete questionnaires and undergo scans during their treatment. It is hoped that findings from this study will help develop new treatment pathways for those with non-metastatic castration-resistant prostate cancer.

Spinal cord injury (SCI) is a life-changing severe injury resulting in substantial physical/psychological impairment. While significant research has investigated adjustment following SCI, very little is known about how co-morbid cognitive impairment impacts adjustment. It is believed around 50% of people with an SCI may have significant levels of cognitive impairment. The Project will employ a mixed methods approach (qualitative and quantitative) utilising implementation science to monitor the efficacy of the implementation and translation process for the 2023 version of the Psychosocial Guidelines (https://aci.health.nsw.gov.au/networks/spinal-cord-injury/resources/psychosocial-care), including guidelines for cognitive impairment, into the SCI Units in Sydney, NSW, Australia by exploring health care professionals and SCI patients’ perceptions towards the implementation of these guidelines. It is hypothesised that the intervention will promote the successful adoption, penetration, and sustainment of the 2023 version of the psychosocial guidelines in the SCI Units.

Whilst most patients are satisfied with their outcomes after a total knee replacement, moderate to severe persistent knee pain, defined as pain persisting beyond 3 post-operative months following surgery, can affect 25% of people at 6-months. NJ’s PhD studies have found associations of persistent high pain with reduced function, and reduced health related quality of life. Other studies have found that pain persisting after a knee replacement can interfere with walking, general activity and mood and reduced quality of life. A literature review conducted as part of NJ’s PhD (unpublished) found no rehabilitation programs addressing persistent pain after knee replacement. NJ, during his PhD studies, has designed a web-based, self-paced, pain rehabilitation program called Kneed to treat pain, reduced function and reduced quality of life for those with persistent pain after total knee replacement for osteoarthritis. The program consists of pain neuroscience education, exercise, motor imagery, desensitization techniques, relaxation, sleep and cognitive strategies such as goal setting. Educational and other strategies aim to normalize movement patterns (by reducing protective movements) and engage participants in functional activities by empowering behavior change. Kneed is being evaluated for the first time in a research study but has been used by patients under clinical supervision from Dr NJ (a Rehabilitation Physician) in a clinical practice. The potential benefit of Kneed as a digital health solution is to provide low-cost treatment to a broad audience, not limited by location (for example, rural areas and cities without pain management services). There are currently no evidence-based treatments available for this persistent pain condition, Kneed aims to provide one.

This study aims to use a Single-Case Experimental Design (SCED) in accordance with SCRIBE (Single-Case Reporting guideline In BEhavioural interventions) to investigate the efficacy of the RARE FINDS (Routine-based intervention, Activity and participation, Repetition and practice, Empowerment and education, Family centered, Individualised, Natural settings, Developmentally appropriate assessment, Start as early as possible) early intervention principles in improving gross motor function and goal attainment for young children living with or at risk of a rare disease (RD). Once the SCED has been completed, families involved in the study will be asked to participate in a 1/2 day workshop style co-design round table discussion which will form part of the qualitative review process of the study, aiming to refine the assessment and intervention components of the study for future studies.

To examine the feasibility and effect of the implementation of a descriptive glycaemic dashboard and proactive endocrinology consult service on glycaemia and glycaemic complications. Patients will be identified via an electronic dashboard with preset criteria of dysglycaemia and randomly assigned to 'standard of care', formal bedside consult, or a default entry on the electronic medical records. We hope to demonstrate that proactive intervention for patients with dysglycaemia will reduce hospital associated infections, as well as a number of other beneficial secondary outcomes.